Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Summary

Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation due to development of tolerance or immunosuppression. This trial combines one drug from each category, immunotherapeutic Nivolumab and chemotherapeutic gemcitabine as it was reported that gemcitabine reduces immunosuppression by killing myeloid derived suppressor cells, thereby increasing the efficacy of Nivolumab.

Timeline

Start

2018-01-15

Primary completion

2019-03-21

Completion

2019-07-12

Drugs

Indications